特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
922047

世界のペプチド治療薬市場:成長、動向、および予測

Peptide Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 112 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
世界のペプチド治療薬市場:成長、動向、および予測
出版日: 2020年06月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 112 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートは世界のペプチド治療薬市場について調査しており、市場機会や動向、成長および阻害要因、マーケティングタイプ・用途・投与経路・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 癌および代謝障害の有病率増加
    • 新薬の研究開発への投資増加
    • 技術の進歩
  • 市場阻害要因
    • ペプチドの不安定性
    • 薬剤承認のための厳しい規制要件
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • マーケティングタイプ別
    • ジェネリック
    • ブランド
  • 用途別
    • 胃腸障害
    • 呼吸器疾患
    • 中枢神経系障害
    • 代謝障害
    • 心血管疾患
    • その他
  • 投与経路別
    • 非経口
    • 経口
    • 経肺
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Eli Lilly and Company
    • Amgen, Inc.
    • Pfizer, Inc.
    • Bristol-Myers Squibb
    • EVER NEURO PHARMA GMBH
    • 武田薬品工業株式会社
    • Teva Pharmaceuticals Industries Ltd
    • AstraZeneca PLC
    • GlaxoSmithKline plc
    • Novo Nordisk A/S.

第7章 市場機会および今後の動向

目次
Product Code: 67574

The peptide therapeutics market is projected to grow with a CAGR of nearly 8.9% over the forecast period. The major factor attributing to the growth of the market is the growing incidence of metabolic disorders and cancers. According to the National Institute of Health (NIH), in 2018, an estimated 1,735,350 new cases of cancer will be detected in the United States and 609,640 people will die from the disease. Furthermore, the increasing demand for efficient and low-cost drugs and rising investments in research and development of novel drugs boost the market growth. However, the limitations associated with peptides and stringent regulatory requirements for drug approval are the major factors restraining market growth.

Key Market Trends

Cancer Segment to Dominate the Market Over the Forecast Period

Peptides offer favorable prospects in targeted drug delivery for cancer due to their high specificity, discernment, small sizes, ease of modification, and high biocompatibility. The increasing frequency of cancer globally and increasing prescription of peptide therapeutics for cancer treatment are the key factors responsible for the dominance of this segment.

According to the World Health Organization (WHO) cancer is the second prominent cause of death worldwide and is accountable for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Furthermore, rising awareness among patients and healthcare professionals regarding adverse effects of chemotherapy and radiation therapy is a major factor for growing focus towards alternative therapeutics such as peptide-based drugs.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to factors such as a rise in awareness levels relating to peptide therapeutics products, increasing necessity for diagnostics in cancer and other diseases, and growing biotechnology industry.

Increasing research and development expenditure by government and key players is also expected to help peptide therapeutics sustain dominance over the coming years. A properly established biopharmaceutical & pharmaceutical industry in this region is a major factor responsible for growth. In the North America region, the United States holds the largest market share due to factors such as an increasing number of research programs in the medical industry, along with a growing number of diseases in the country, which is anticipated to stimulate the demand in this region.

Competitive Landscape

The peptide therapeutics market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Eli Lilly and Company; Pfizer, Inc.; Amgen, Inc.; Bristol-Myers Squibb; EVER NEURO PHARMA GMBH; Takeda Pharmaceutical Company Limited; Teva Pharmaceuticals Industries Ltd.; AstraZeneca PLC; GlaxoSmithKline plc; and Novo Nordisk A/S.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cancer and Metabolic Disorders
    • 4.2.2 Rising Investments in Research and Development of Novel Drugs
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 Limitations Associated with Peptides
    • 4.3.2 Stringent Regulatory Requirements for Drug Approval
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Marketing type
    • 5.1.1 Generic
    • 5.1.2 Branded
  • 5.2 By Application
    • 5.2.1 Gastrointestinal Disorders
    • 5.2.2 Respiratory Disorders
    • 5.2.3 Central Nervous System Disorders
    • 5.2.4 Cancer Disorders
    • 5.2.5 Cardiovascular Diseases
    • 5.2.6 Others
  • 5.3 By Route of Administration
    • 5.3.1 Parenteral
    • 5.3.2 Oral
    • 5.3.3 Pulmonary
    • 5.3.4 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Eli Lilly and Company
    • 6.1.2 Amgen, Inc.
    • 6.1.3 Pfizer, Inc.
    • 6.1.4 Bristol-Myers Squibb
    • 6.1.5 EVER NEURO PHARMA GMBH
    • 6.1.6 Takeda Pharmaceutical Company Limited
    • 6.1.7 Teva Pharmaceuticals Industries Ltd
    • 6.1.8 AstraZeneca PLC
    • 6.1.9 GlaxoSmithKline plc
    • 6.1.10 Novo Nordisk A/S.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.